MediSix Therapeutics is a development-stage cell therapy company creating chimeric antigen receptor (CAR‑T) T‑cell therapies to treat T‑cell leukemia and lymphoma. The company holds an exclusive licensing agreement with the National University of Singapore (NUS) and also has rights to an underlying cell engineering platform that could enable applications beyond T‑cell malignancies. MediSix plans to use its Series A financing to build out the team, advance product development, and initiate early pre‑clinical studies. The company announced the appointment of Murray Robinson, PhD, as Chief Scientific Officer; he brings more than 25 years of oncology drug‑discovery and development experience. Founded by Professor Dario Campana of NUS, MediSix is positioned to translate university‑originated CAR‑T innovations into clinical candidates. The company is based in Singapore and remains in pre‑clinical development.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

May 2018